welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Modelling Duchenne Muscular Dystrophy in MYOD1-Converted Urine-Derived Cells Treated With 3-Deazaneplanocin A Hydrochloride
source: Scientific Reports
year: 2019
authors: Takizawa H, Hara Y, Mizobe Y, Ohno T, Suzuki S, Inoue K, Takeshita E, Shimizu-Motohashi Y, Ishiyama A, Hoshino M, Komaki H, Takeda S, Aoki Y
summary/abstract:Duchenne muscular dystrophy (DMD) is a severe muscle disorder characterised by mutations in the DMD gene. Recently, we have completed a phase I study in Japan based on systemic administration of the morpholino antisense that is amenable to exon-53 skipping, successfully. However, to achieve the effective treatment of DMD, in vitro assays on patient muscle cells to screen drugs and patient eligibility before clinical trials are indispensable. Here, we report a novel MYOD1-converted, urine-derived cells (UDCs) as a novel DMD muscle cell model.
We discovered that 3-deazaneplanocin A hydrochloride, a histone methyltransferase inhibitor, could significantly promote MYOGENIN expression and myotube differentiation. We also demonstrated that our system, based on UDCs from DMD patients, could be used successfully to evaluate exon-skipping drugs targeting DMD exons including 44, 50, 51, and 55. This new autologous UDC-based disease modelling could lead to the application of precision medicine for various muscle diseases.
organization: National Center of Neurology and Psychiatry, Japan; Tokyo Medical and Dental University, JapanDOI: 10.1038/s41598-019-40421-z
read more
rareRelated
-
Exon Skipping Explained from Sarepta Therapeuticshttps://player.vimeo.com/video/238953537...
-
Exploratory Study of NS-089/NCNP-02 in DMDThis study is designed to assess the saf...
-
MLPA Analyses Reveal a Spectrum of Dystrophin Gene Deletions/Duplications in Pakistani Patients Suspected of Having ...Introduction: Duchenne muscular dystr...
-
Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial DesignWave Life Sciences Ltd., a clinical-stag...
-
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular DystrophyThe primary objective of this study is t...
-
Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular DystrophyThis is a multicenter, open-label, long-...
-
Annemieke Aartsma-Rus, PhDDr. Annemieke Aartsma-Rus played an impo...
-
ICER Document Reviews Effectiveness of 3 Duchenne MD TherapiesThe Institute for Clinical and Economic ...